Your session is about to expire
← Back to Search
Palbociclib + Chemotherapy for Acute Lymphoblastic Leukemia
Study Summary
This trial is testing the safety and effectiveness of a new cancer drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 55 Patients • NCT03007979Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You can breathe comfortably and have no trouble exercising, and your oxygen levels are above 94%.If you have taken bortezomib or other similar drugs in the past and they didn't work for you, you cannot participate. But if you had a good response initially and then the condition came back, you can still participate.You need to wait for at least 42 days after receiving CAR T cell therapy.You have taken a medication called palbociclib or other drugs that work similarly to it in the past.You have had a bone marrow transplant and your disease has come back.You are currently receiving chemotherapy or targeted anti-cancer medications, except for medications that are directly delivered into the spinal canal (intrathecal therapy).
- Group 1: Cohort 1 -(without Ph+ / Ph like mutation)
- Group 2: Cohort 2-(Ph+ / Ph like ALL subtypes):
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions does Palbociclib commonly address?
"Palbociclib is typically prescribed to address synovitis, however it may also offer relief from ophthalmia, sympathetic conditions, branch retinal vein occlusion and macular edema."
What adverse effects have been observed with Palbociclib usage?
"Due to its status as a Phase 1 trial, which has limited data on safety and efficacy, Palbociclib's risk is estimated at 1 by the Power team."
Are there any open slots in this experiment for participants?
"This medical study is actively searching for new participants, as confirmed by data hosted on clinicaltrials.gov. It was first posted in July 2021 and the most recent update occurred two months later in September 2021."
Has Palbociclib been tested in any other scientific investigations?
"Currently, 1027 clinical trials for Palbociclib are in progress. Of these, 258 have moved past Phase 3 of the process and Joliet, Illinois is home base to many studies related to this treatment. However, it can be found at a total of 46926 research locations worldwide."
Is this research the initial examination of its type?
"Palbociclib has had a long history of observed research, with the inaugural trial sponsored by Alfacell in 1997. After this first study involving 300 participants, Palbociclib was given Phase 3 drug approval. Currently, 1027 studies regarding this medication are ongoing across 2763 cities and 80 countries."
What is the scope of participants for this research experiment?
"Affirmative. One can find that the clinical trial is currently open to recruit participants on clinicaltrials.gov, which was first published in July 9th 2021 and recently edited on September 20th 2021; this research project aims to enroll 22 individuals across one facility."
Share this study with friends
Copy Link
Messenger